WPG Advisers’s Denali Therapeutics DNLI Stock Holding History

WPG Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.65K	Buy	142 +76	+115%	+$1.56K	﹤0.01%	1052
2026 Q1	$1.27K	Buy	+66	New	+$1.31K	﹤0.01%	1209

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WPG Advisers's DNLI Position: Q2 2026 in Review

WPG Advisers increased its Denali Therapeutics (DNLI) stake by 115% in Q2 2026, buying an estimated $1.56K and bringing the position to 142 shares worth $3.65K. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

WPG Advisers first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

WPG Advisers held 142 shares of Denali Therapeutics worth $3.65K as of Q2 2026.
WPG Advisers bought 76 Denali Therapeutics shares in Q2 2026, an estimated $1.56K.
Denali Therapeutics made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #1052 holding.
WPG Advisers first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.